Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Panelists discuss how the preliminary results from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory multiple myeloma (R/R MM) highlight promising efficacy in triple-class and penta-class refractory patients, potentially reshaping treatment strategies and challenging existing paradigms in managing heavily pretreated myeloma.

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with relapsed/refractory multiple myeloma (R/R MM), highlighting the critical importance of translating clinical trial data into practical treatment strategies.

Application of Real-World Evidence in Selecting CAR T in R/R MM

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Heinz-Josef Lenz, MD, and Van Karlyle Morris, MD, discuss the significance of the FDA approval of nivolumab plus ipilimumab for MSI-H/dMMR mCRC.  

Nivolumab/Ipilimumab Stands as the SOC for MSI-H/dMMR mCRC

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Pyrotinib led to high 2-year iDFS rates in the adjuvant setting following adjuvant trastuzumab-based treatment in HER2-positive breast cancer.

Extended Adjuvant Pyrotinib Shows Promising Efficacy After Trastuzumab-Based Therapy in HER2+ Breast Cancer

Aiwu Ruth He, MD, PhD, discusses data from the CheckMate 9DW trial that supported the FDA approval of frontline nivolumab plus ipilimumab for advanced HCC.

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

CME Opportunities

Specialty

OncLive Peer Exchange®

Perspectives on Metastatic Kidney Cancer

Videos

Prognostic and Predictive Factors in Renal Cell Carcinoma

Treating Intermediate and Favorable-Risk RCC

Reviewing Results from COMPARZ and PISCES Clinical Trials

Dosing Sunitinib and Pazopanib in Renal Cell Carcinoma  

Bone and Brain Metastases in Renal Cell Carcinoma

Treating Non-Clear Cell Renal Cell Carcinoma 

Managing Disease Progression in RCC

Selecting Second-Line Agents in Renal Cell Carcinoma 

Predictive Tools in Renal Cell Carcinoma 

Clinical Trial Data Review: Nivolumab Use in RCC

Trial Data on Cabozantinib in Renal Cell Carcinoma

PD-L1 Expression as a Biomarker in RCC

Study Results: Lenvatinib in Renal Cell Carcinoma

Vaccines for Renal Cell Carcinoma

Advancing Renal Cell Carcinoma

Perspectives on Metastatic Kidney Cancer

Latest Conference Coverage